# Optimum Induction Therapy of Low-risk APL

> **NCT05832320** · NA · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 74 (estimated)

## Conditions studied

- Acute Promyelocytic Leukemia
- Induction Therapy
- Oral

## Interventions

- **DRUG:** Etoposide
- **DRUG:** Daunorubicin

## Key facts

- **NCT ID:** NCT05832320
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05832320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05832320, "Optimum Induction Therapy of Low-risk APL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05832320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*